The Present and Future of Biosimilars: Opportunity Abounds

So where are we now with biosimilars? Patent expirations and new bioanalytical advancements over the past couple of years have driven much debate about the development of biosimilars, and the potential threat that these present for current originator products.

Dominique Gouty, Ph.D., of BioAgilytix, offers her expert opinion in this Virtual Podium presentation.

Related Presentations

Biomarkers for Heart Disease in African American Women with Lupus

Biomarkers for Heart Disease in African American Women with Lupus

Seeking the Biomarkers of Alzheimer's Disease - On Our Mind

Seeking the Biomarkers of Alzheimer's Disease - On Our Mind

An Analytical Approach to Platform Comparison

An Analytical Approach to Platform Comparison